Lifestyle Intervention, Metformin and Multimorbidity Risk in Prediabetes; Hypertension, Hyperlipidemia and Chronic Kidney Disease, Resistance Training & Myocardial Infarction
Eagle's Eye View: Your Weekly CV Update From ACC.org
Release Date: 06/24/2026
Age, BMI, & TAVR; Enhanced Radiation Protections in Cath Labs; Particulate Matter and CV Risk; the SUMMIT Trial & Tirzepatide.
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at age, body mass index (BMI), and cardiovascular outcomes after transcatheter aortic valve replacement (TAVR). He follows this with an examination of a new consensus statement about enhanced radiation protection in cath labs, then offers a perspective on particulate matter in the environment and increased coronary heart disease risk. Finally, Dr. Eagle provides an analysis of the SUMMIT Trial, showing the benefit of...
info_outline
Mechanical Leaflet Splitting and TAVR; Ambient Temperature & Marathons; AFib, PVI with PA & IRF; the SHaRE Registry as a Predictor of MACE
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at the feasibility of mechanical leaflet splitting in high-risk patients undergoing valve-in-valve TAVR. He follows this with an examination of lower ambient temperature and it association with greater SCA risk at marathon races, then offers a commentary on two studies that provide new insights on the durability of pulmonary vein isolation (PVI) with pulsed field ablation (PA) vs radiofrequency ablation IRF) in patients with persistent atrial fibrillation (AFib). Finally, Dr. Eagle discusses the SHaRe Registry and its use in predicting major...
info_outline
Guideline-Directed Medical Therapy & Atrial Fibrillation; Anti-Platelet Therapy & ASCVD; DOACs & Prevention of Thrombotic Events; Sugar-Sweetened Beverages and Fruit Juice & Hypertension
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at withdrawing guideline-directed medical therapy (GDMT) for patients with atrial fibrillation (AF). He follows this with commentary on two important recently released ACC scientific statements: one on anti-platelet therapy for atherosclerotic cardiovascular disease (ASCVD), and the other examining the use of direct oral anticoagulants (DOACs) for primary and secondary prevention of thrombotic events. Finally, Dr....
info_outline
Genotype and Hypertrophic Cardiomyopathy; PARTNER 2A & TAVR 10 Years Later; Clopidogrel vs. Aspirin after PCI; LDL & Risk Assessment of ASCVD
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM). He then examines the ten-year follow-up of the PARTNER 2A trial and compares the transcatheter aortic valve replacement (TAVR) outcomes to results from the Partner 2 SAPIEN XT and SAPIEN 3 studies. He follows this with a report on how clopidogrel may offer a long-term edge over aspirin after percutaneous coronary intervention (PCI). Finally,...
info_outline
Lifestyle Intervention, Metformin and Multimorbidity Risk in Prediabetes; Hypertension, Hyperlipidemia and Chronic Kidney Disease, Resistance Training & Myocardial Infarction
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle reviews 21-year follow-up data from the Diabetes Prevention Program (DPP), showing that lifestyle intervention—but not metformin—reduces multimorbidity risk in prediabetes. He also highlights low rates of hypertension and hyperlipidemia treatment among U.S. adults with cardiovascular-kidney-metabolic (CKM) syndrome, and summarizes evidence that resistance training, particularly when combined with aerobic exercise, is associated with a lower risk of cardiovascular (CV) disease, especially myocardial infarction, in women. Finally, he discusses...
info_outline
Race and Sex Disparities in Mitral Valve Edge-to-Edge Repair
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle highlights a study showing race and sex disparities in M-TEER outcomes, with Black patients presenting with more advanced disease, lower success, and higher heart failure readmissions than White patients, and women having lower success rates than men. He reviews the SOGALDI-PEF trial, where patients with low plasma renin levels experienced greater blood pressure reduction with spironolactone/dapagliflozin compared to dapagliflozin alone. Next, he discusses the FAVOR III trial, which found that QFR-guided percutaneous coronary...
info_outline
Impact of Semaglutide And Survival Outcomes In Patients With T2D and CKD
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle highlights several noteworthy developments shaping cardiovascular and renal care. He first examines the FLOW analysis, underscoring the benefits of semaglutide for patients with chronic kidney disease, with particular attention to its impact on both renal and cardiovascular outcomes. He then reviews a phase I study exploring an innovative therapeutic approach involving a single intravenous infusion—Verve-2—which targets PCSK9 expression in the liver and may represent a promising future strategy for treating familial hyperlipidemia. Finally,...
info_outline
Postpartum Cardiovascular Care; ‘Low Risk’ Chest Pain in the ER; Heart Failure Risk Detection & CV Outcomes with Implantable Devices
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at recent research found in ACC’s new expert decision pathway for postpartum cardiovascular care. He then offers insights from the ACC Chest Pain - MI Registry examining ‘low risk’ chest pain and its evaluation in the emergency departments. Next, a discussion of how negative patient outcomes were associated with late pericardial effusion post-left atrial appendage occlusion (LAAO) device...
info_outline
Maintaining Weight Loss with Tirzepatide; the new Dyslipidemia Guidelines; Sacubitril/Valsartan & HFpEF & Functional MR; Digitoxin & Heart Failure
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle examines recent research into maintaining weight loss with tirzepatide. He then offers insights into the new dyslipidemia guidelines, including addressing reproductive and hormone risk factors in cardiovascular risk assessment. Next, Dr. Eagle looks at the use of sacubitril/valsartan to improve exercise tolerance in patients with heart failure with reduced ejection fraction (HFpEF) and functional mitral regurgitation (MR). Finally, Dr. Eagle summarizes a new...
info_outline
HCM, NT-proBNP and HCM Risk Evaluation; Arrhythmic Burden in Cardiac Amyloidosis Obesity and Heart Failure; Postural Orthostatic Tachycardia Syndrome (POTS)
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle reviews evidence supporting the use of cardiac magnetic resonance (CMR) and NT-proBNP in hypertrophic cardiomyopathy (HCM) risk assessment. He then examines the EXCALIBUR study, which aims to better characterize arrhythmic burden in patients with cardiac amyloidosis. Next, he discusses research identifying obesity as a significant risk factor for heart failure, highlighting key findings and clinical implications. Finally, he summarizes new evidence on the use of ivabradine and propranolol in treating postural orthostatic tachycardia...
info_outlineIn this week’s View, Dr. Eagle reviews 21-year follow-up data from the Diabetes Prevention Program (DPP), showing that lifestyle intervention—but not metformin—reduces multimorbidity risk in prediabetes. He also highlights low rates of hypertension and hyperlipidemia treatment among U.S. adults with cardiovascular-kidney-metabolic (CKM) syndrome, and summarizes evidence that resistance training, particularly when combined with aerobic exercise, is associated with a lower risk of cardiovascular (CV) disease, especially myocardial infarction, in women. Finally, he discusses the CAMERA-MRI II study in patients with atrial fibrillation and left ventricular systolic dysfunction (LVSD), where catheter ablation significantly improved left ventricular ejection fraction (LVEF) regardless of late gadolinium enhancement status.